Viral load as a primary outcome in human immunodeficiency virus trials: a review of statistical analysis methods.

In Human Immunodeficiency Virus infection, several statistical methods are available to analyze viral load (HIV-1 RNA) used as a surrogate outcome in trials of antiretroviral treatments. We compared the most frequently used methods and applied them to one of these trials, where HIV-1 RNA was measured using two lower limits of detection. Methods were reviewed for different properties dealing with validity, interpretation, and handling. Compared to change of HIV-1 RNA at the end of follow-up or HIV-1 RNA area-under-the-curve during follow-up minus baseline, the most attractive methods appeared to be HIV-1 RNA undetectability, HIV-1 RNA reduction at the end of follow-up with censoring adjustment, and mixed linear model on HIV-1 RNA.

[1]  Á. Holguín,et al.  Comparison of Three Different Commercial Methods for Measuring Plasma Viraemia in Patients Infected with Non-B HIV-1 Subtypes , 1999, European Journal of Clinical Microbiology and Infectious Diseases.

[2]  S. Hammer,et al.  Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. , 1998, The Journal of infectious diseases.

[3]  I P Keet,et al.  Longitudinal analysis of CD4 T cell counts, T cell reactivity, and human immunodeficiency virus type 1 RNA levels in persons remaining AIDS-free despite CD4 cell counts <200 for >5 years. , 1997, The Journal of infectious diseases.

[4]  D Commenges,et al.  Analysis of left-censored longitudinal data with application to viral load in HIV infection. , 2000, Biostatistics.

[5]  John P. A. Ioannidis,et al.  NIAID Workshop, Memphis, Tennessee, 25-26 March 1997: Statistical issues for HIV surrogate endpoints: Point/counterpoint , 1998 .

[6]  W J Boscardin,et al.  Longitudinal models for AIDS marker data , 1998, Statistical methods in medical research.

[7]  R. H. Jones,et al.  Unequally spaced longitudinal data with AR(1) serial correlation. , 1991, Biometrics.

[8]  M A Fischl,et al.  Antiretroviral Therapy in Adults Updated Recommendations of the International AIDS Society–USA Panel , 2000 .

[9]  M. Peeters,et al.  Comparison of the QUANTIPLEX HIV-1 RNA 2.0 Assay with the AMPLICOR HIV-1 MONITOR 1.0 Assay for Quantitation of Levels of Human Immunodeficiency Virus Type 1 RNA in Plasma of Patients Receiving Stavudine-Didanosine Combination Therapy , 1998, Journal of Clinical Microbiology.

[10]  M. Hughes,et al.  Monitoring Plasma HIV-1 RNA Levels in Addition to CD4+ Lymphocyte Count Improves Assessment of Antiretroviral Therapeutic Response , 1997, Annals of Internal Medicine.

[11]  R A Betensky,et al.  Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases. , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[12]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[13]  M. Saag.  Use of virologic markers in clinical practice. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[14]  J. Delfraissy,et al.  Prise en charge thérapeutique des personnes infectées par le VIH , 2000 .

[15]  J M Taylor,et al.  Statistical issues for HIV surrogate endpoints: point/counterpoint. An NIAID workshop. , 1998, Statistics in medicine.

[16]  J. Dawson.  Comparing Treatment Groups on the Basis of Slopes, Areas-Under-the-Curve, and other Summary Measures , 1994 .

[17]  J. Montaner,et al.  Estimates of the virological benefit of antiretroviral therapy are both assay‐ and analysis‐dependent , 1998, AIDS.

[18]  G. Chêne,et al.  The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus. , 1999, The Journal of infectious diseases.

[19]  P. Diggle.  An approach to the analysis of repeated measurements. , 1988, Biometrics.

[20]  J. Ware,et al.  Random-effects models for longitudinal data. , 1982, Biometrics.

[21]  D. Schoenfeld,et al.  AIDS clinical trials , 1995 .

[22]  J. Singer,et al.  Issues in the design of trials of therapies for subjects with human immunodeficiency virus infection that use plasma RNA level as an outcome. , 1997, The Journal of infectious diseases.

[23]  Robert W. Coombs,et al.  Longitudinal Analysis of Quantitative Virologic Measures in Human Immunodeficiency Virus-Infected Subjects with ⩾400 CD4 Lymphocytes: Implications for Applying Measurements to Individual Patients , 1997 .

[24]  A L Gould,et al.  A new approach to the analysis of clinical drug trials with withdrawals. , 1980, Biometrics.

[25]  D. Rubin,et al.  Statistical Analysis with Missing Data. , 1989 .

[26]  A. Phillips,et al.  Trial design in the era of highly effective antiviral drug combinations for HIV infection. , 1998, AIDS.

[27]  M. Elashoff,et al.  The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. , 1999, AIDS.

[28]  Steve Selvin,et al.  Statistical Analysis of Epidemiologic Data , 1991 .

[29]  J. Hughes,et al.  Mixed Effects Models with Censored Data with Application to HIV RNA Levels , 1999, Biometrics.

[30]  B Wise,et al.  Antiretroviral therapy in adults. , 1996, Journal of the American Academy of Nurse Practitioners.

[31]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[32]  S. Hammer,et al.  Virologic and regimen termination surrogate end points in AIDS clinical trials. , 2001, JAMA.